Researchers pursuing answers to KRAS-mutated lung cancer and ovarian cancer prevention in MD Anderson's Moon Shots Program are chosen for similar roles in SU2C Dream Teams.
Long non-coding RNAs (lncRNA) are unusual in that they don’t encode proteins like normal RNA. Yet they do play a role in regulating cellular functions and interest cancer researchers.
Mutations of the KRAS gene are commonly known to lead to cancer. However, deeper understanding of exactly how they do this continues to be explored by cancer researchers.
Cancer scientist James Allison, Ph.D., internationally known for his role in developing a new class of cancer immunotherapies, has been named a recipient of the 2015 Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research. The award will be presented to Allison, at the 2015 AACR Annual Meeting, to be held in Philadelphia, April 18-22.
The prospect of combining genomically targeted therapies with drugs that free the immune system to attack cancer suggests “we are finally poised to deliver curative therapies to cancer patients,” researchers at The University of Texas MD Anderson Cancer Center note in a review in the April 9 edition of Cell.
The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc. have signed an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).
Spreading the success of cancer immunotherapy beyond those patients currently enjoying powerful, long-term responses to treatment requires greater understanding of the immune response to tumors, two leaders in the field note in a review in the April 3 Science.
The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString’s nCounter® Analysis System.
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by researchers at The University of Texas MD Anderson Cancer Center.
Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, received the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize Saturday in recognition of his work opening a completely new way to treat cancer.
Scientists at The University of Texas MD Anderson Cancer Center have discovered new information about a key pathway known as Hippo, a metaphoric name referencing its link to tissue “overgrowth.” The Hippo pathway has been shown to regulate cell death and cell growth, thus playing a role in the development or prevention of tumors.
Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide.
A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor – a milestone strongly tied to improved survival.
Patrick Hwu, M.D., chair of Melanoma Medical Oncology and Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center, has been named division head of Cancer Medicine effective March 4.
Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein’s power to spur cancer cell growth.
The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas (CPRIT).
Tumors require blood to emerge and spread. That is why scientists at The University of Texas MD Anderson Cancer Center believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach when combined with vascular growth factors responsible for cell death.
Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings nationwide, to promote behavior that will lower children’s lifelong risk of developing cancer.
Ron DePinho, M.D., president of The University of Texas MD Anderson Cancer Center, will be inducted as a new fellow of the American Association for Cancer Research (AACR) Academy.
The University of Texas MD Anderson Cancer Center returns March 7 to Sarasota, Fla., for the institution’s annual Making Cancer History® seminar at the Hyatt Regency Sarasota, 1000 Blvd. of the Arts.
The importance of RNA editing in melanoma has been demonstrated by scientists at The University of Texas MD Anderson Cancer Center. The study revealed that a lack of RNA editing, a process by which information inside RNA molecules is transformed, leads to tumor growth and progression through manipulation of proteins.
Raghu Kalluri, M.D., Ph.D., chair, cancer biology at The University of Texas MD Anderson Cancer Center, has received a notable scientific award from a top German university.
In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.
When skyscrapers go up, contractors rely on an infrastructure of steel beams and braces. Some cancers grow the same way, using a biological matrix from which the tumor can thrive and spread.
Scottish author Robert Louis Stevenson tapped into primal fears when he penned “Dr. Jekyll and Mr. Hyde,” a 19th century novel about a sinister physician, raising the question, “Can evil and good exist in the same person?”
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published in the journal Cancer, could offer clinicians the ability to better communicate with patients and families. They may also guide both the medical team and caregivers on complex decision making, such as discontinuation of tests and therapy, plans for hospital discharge and hospice referral.
The University of Texas MD Anderson Cancer Center and AstraZeneca today announced a multiyear strategic research collaboration to conduct multiple, parallel clinical and clinically related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.
A new collaboration between Bayer and The University of Texas MD Anderson Cancer Center will go straight to the patients to learn how certain investigational new drugs affect them. The project will involve the use of questionnaires to assess how a drug may impact a patient’s disease-related symptoms.
The University of Texas MD Anderson Cancer Center was presented the People’s Republic of China International Science and Technology Cooperation Award at a ceremony held Jan. 9 at Beijing’s Great Hall of the People.
With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors, according to research from The University of Texas MD Anderson Cancer Center.
Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen’s bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a “bridge” between T cells and cancer cells.
Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug.
The University of Texas MD Anderson Cancer Center and UnitedHealthcare have launched a pilot to explore a new cancer care payment model for head and neck cancers that focuses on quality patient care and outcomes.
The Food and Drug Administration’s (FDA) approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center.
MD Anderson study finds no association with assay and decreased chemotherapy use in older patients.
A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.
Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T cells has demonstrated further promise in patients with advanced hematologic malignancies.
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
Peter Friedl, M.D., Ph.D., professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center, has received one of Italy’s top scientific awards for his work in imaging and cancer growth, metastasis and therapy response.
Their responsibilities may range from exploring the intricacies of biostatistics to bringing new drugs more rapidly to the patient, but eight faculty members from The University of Texas MD Anderson Cancer Center all share one honor – being named as Fellows by the American Association for the Advancement of Science.
A protein kinase or enzyme known as PKM2 has proven to control cell division, potentially providing a molecular basis for tumor diagnosis and treatment.
It’s hard to believe, but there are similarities between bean sprouts and human cancer.
Scientists have found that altering members of the p53 gene family, known as tumor suppressor genes, causes rapid regression of tumors that are deficient in or totally missing p53.
Molecules called long non-coding RNAs (lncRNAs) have been implicated in breast cancer but exactly why they cause metastasis and tumor growth has been little understood…until now.
Houston, Texas -- For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society’s (IGCS) Award of Excellence.
November 5, 2014 – In the next 15 years, more than one in 10 colon cancers and nearly one in four rectal cancers will be diagnosed in patients younger than the traditional screening age, according to researchers at The University of Texas MD Anderson Cancer Center.
In terms of duration of treatment and cost, patients with early stage breast cancer may benefit from accelerated partial breast irradiation (APBI) with proton therapy versus whole breast irradiation (WBI), according to new research from The University of Texas MD Anderson Proton Therapy Center.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right